Roche Reports P-III (IMscin001) Study Results of Subcutaneous Formulation of Tecentriq for the Treatment of Non-Small Cell Lung Cancer
Shots: The P-III (IMscin001) study evaluating the PK, safety & efficacy of Tecentriq as SC formulation vs IV Tecentriq in 371 patients with prior treated […]